Niraparib metabolite M1 - 10mM in DMSO , CAS No.1476777-06-6

CAS: 1476777-06-6 Cat. No.: N655679 Formula: C₁₉H₁₉N₃O₂ Molecular Weight: 321.37 PubChem CID: 118737587

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase ( PARP ) inhibitor.

In Vitro

Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Specifications

Specifications & Purity

10mM in DMSO

Biochemical and Physiological Mechanisms

Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase ( PARP ) inhibitor.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Names and Identifiers

Isomeric SMILES

C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)O

PubChem CID

118737587

Molecular Weight

321.37

Application Protocols

General protocols for use as an analytical reference standard (adapt to institutional SOPs):

• Stock solution preparation:
  • Equilibrate vial to room temperature in a desiccator before opening to avoid condensation.
  • Prepare a concentrated stock in anhydrous DMSO (e.g., 10–20 mg/mL) or in methanol/acetonitrile for lower concentrations. Vortex and, if needed, sonicate briefly. Record exact weight and purity for concentration correction.
• Calibration/QC solutions:
  • Serially dilute stock into 50:50 water:acetonitrile (or methanol) with 0.1% formic acid to prepare working standards.
  • Spike into blank matrix to prepare matrix-matched calibrators and QCs; verify recovery, matrix factor, and process efficiency.
• System suitability:
  • Inject a mid-level standard to verify retention time stability and peak shape. Monitor signal-to-noise and backpressure trends.
• Stability assessment:
  • Test bench-top (≥4 h), autosampler (≥24 h at 4–10°C), and ≥3 freeze–thaw cycles. Establish acceptance criteria (e.g., within ±15%).
• Documentation:
  • Retain CoA/SDS, preparation records, chromatograms, and calculations. Apply purity correction (assay %) for nominal concentrations.

Note: Concentration ranges, transitions, and exact instrument settings must be established empirically; none are specified for this item.

Biological Roles

General, literature-based context for niraparib metabolism (no clinical claims):

• Origin: M1 denotes a primary metabolite of niraparib formed via Phase I and/or Phase II biotransformation pathways. Common transformations for drug-like molecules include oxidative modifications (e.g., N- or O-dealkylation, hydroxylation) and conjugations (e.g., glucuronidation, sulfation); the exact identity for M1 must be confirmed from the CoA/literature.
• Enzymology (general): Phase I metabolism is typically mediated by cytochrome P450 isozymes; conjugations involve UGTs or SULTs. The involvement of specific enzymes for M1 should be determined experimentally or from the literature.
• Pharmacokinetic relevance: As a defined metabolite standard, M1 enables investigations of formation rates, clearance pathways, and distribution in preclinical matrices. It supports quantitation in mass balance and metabolite profiling studies.
• Analytical significance: Access to authentic M1 improves confidence in metabolite identification, peak assignment, and quantitation, reducing ambiguity from isobaric species.

Note: This section provides biochemistry-oriented context only. The product is for research use in analytical/biochemical studies and is not intended for diagnostic or therapeutic use.

Buffer Applications

This product is a small-molecule metabolite standard and is not a buffering agent. There are no conventional buffer-capacity applications.

Practical note for analytics:

• For LC–MS/MS assays, volatile buffers such as 2–10 mM ammonium acetate or ammonium formate, optionally with 0.05–0.2% formic acid, are commonly used to control ionization and peak shape. Optimize pH/additives empirically for M1.
• Avoid non-volatile salts and high phosphate concentrations in ESI-based methods due to ion suppression.

Green Alternatives

While the compound itself is fixed, greener choices can be made in solvent systems and workflows for its analytical use.

Greener solvent considerations (literature/general):

• Replace a portion of acetonitrile with ethanol or methanol when chromatographic performance permits; methanol and ethanol have preferable EHS profiles vs. acetonitrile.
• Use aqueous-rich gradients and lower flow rates to reduce solvent consumption.
• Consider supercritical fluid chromatography (SFC, CO2-based) when analyte solubility and detection allow; this can significantly reduce organic solvent use.
• For protein precipitation, switch from acetonitrile to ethanol or isopropanol where recovery and matrix effects remain acceptable.

Comparison (general guidance):

• Acetonitrile: strong elution power, sharp peaks; higher environmental burden and supply volatility.
• Methanol: greener, cost-effective; may require longer runs or modified gradients.
• Ethanol: greener but higher viscosity; check backpressure and peak shape.

Operational practices:

• Scale down assay volumes (micro-LC, UHPLC) and use multiwell formats to minimize waste.
• Implement solvent recycling/purification where appropriate.

Trade-offs should be validated for sensitivity, selectivity, and robustness in your LC–MS/MS method.

Pharmaceutical Uses

No therapeutic or clinical uses are claimed for this product. It is intended strictly for research and analytical purposes.

Relevant roles in pharmaceutical R&D and quality (general):

• Reference standard for bioanalytical methods supporting preclinical studies: calibration/QC materials for quantifying M1 in biological matrices.
• Metabolite profiling and mass balance studies: facilitate identification and tracking of M1 in in vitro and in vivo samples.
• Stability-indicating methods: use as a marker to challenge specificity of chromatographic methods for niraparib and related species.
• Impurity/related substance assessment: potential use in method development for drug substance/product characterization where metabolite carryover or formation is studied.

Documentation expectations:

• Maintain CoA, SDS, and spectral data in analytical files.
• Apply purity correction (assay on as-is vs. anhydrous basis) for gravimetric standard preparation.
• For regulated contexts, qualify the standard per internal SOPs (identity, purity, stability) before use.

Physical Properties

Item-specific specifications are not provided in the Product Data and must be confirmed on the CoA/SDS.

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Melting point (literature/general): Not available; check CoA.
• Boiling point (literature/general): Not applicable for most solid analytical standards; check CoA.
• Density (literature/general): Not available; check CoA.
• Solubility (practical guidance): Analytical metabolites of drug-like molecules are typically soluble in DMSO and may dissolve in acetonitrile or methanol. Begin with 10–20 mg/mL in dry DMSO, then dilute into aqueous buffers (≤1–2% DMSO v/v) for LC–MS/MS; verify experimentally for your lot.
• LogP/pKa (literature/general): Not specified here; consult literature or determine experimentally for method development (affects chromatographic behavior and ionization efficiency).
• UV–Vis (literature/general): PARP inhibitor scaffolds often show UV absorbance in the 230–300 nm region; confirm for M1 experimentally.

Notes:

• Treat all physical parameters above as method-development starting points only. For regulated work, defer to CoA and internal method validation.

Quality and Grades

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet. Typical offerings for analytical metabolite standards are ≥95% by HPLC/UPLC unless otherwise stated, but the definitive specification is on the CoA.

What to look for on the CoA/Spec Sheet:

• Assay and related substances: % area normalization by HPLC/UPLC, with impurity thresholds and reporting limits.
• Identity: LC–MS (accurate mass), and where applicable 1H/13C NMR. Provide acceptance criteria (m/z tolerance, retention time window vs. reference).
• Water/Residual Solvents: Not specified for this item; refer to CoA/Spec Sheet.
• Counter-ions/Crystal form: Clarify if supplied as free base/neutral species or salt form; polymorph/solvate status if applicable.
• Stability: Storage and retest/expiry date under specified conditions.

Practical implications:

• Higher purity minimizes co-eluting signals and ion suppression in LC–MS/MS bioanalysis.
• If supplied as a salt, adjust calculations for molar concentration accordingly.
• For quantitative work (calibration/QC samples), verify purity and correct for assay on anhydrous basis when preparing gravimetric standards.

Reaction and Applications

Primary use-cases for Niraparib metabolite M1 are analytical and mechanistic rather than synthetic transformations.

• Bioanalytical reference standard:
  • Calibration curves and quality controls in LC–MS/MS quantification of niraparib and its metabolites in plasma, tissue homogenates, microsomes, or hepatocyte incubations.
  • Method transfer and cross-validation between laboratories; evaluate selectivity against endogenous interferences.
• Metabolism and ADME studies:
  • Benchmark for in vitro biotransformation investigations (e.g., human liver microsomes, S9, hepatocytes) to verify M1 identity/retention versus in situ formed metabolites.
  • Time-course stability and interconversion assessments under sample preparation conditions (pH, temperature, light).
• Mechanistic/Pathway studies (general):
  • Supports elucidation of niraparib metabolic routes (e.g., oxidative, N-dealkylation, conjugation), without asserting a specific structure here; confirm with CoA/literature.
• Chromatographic method development:
  • Optimize stationary phase selection (C18, phenyl-hexyl, polar-embedded) and mobile-phase additives (formic acid, ammonium formate/acetate) for resolution of isobaric/isomeric metabolites.

Practical tips:

• Employ isotopically labeled internal standards where possible.
• Assess matrix effects via post-extraction spiking and recovery experiments.
• Validate short- and long-term stability in matrix and extract (autosampler, bench-top, freeze–thaw).

Reaction Conditions

This product is not primarily a reagent for chemical synthesis; therefore, no canonical “reaction conditions” apply. For its core use in LC–MS/MS quantitation, the following general method-development conditions (literature/practice) are provided:

• Sample preparation: Protein precipitation with 3–4 volumes of acetonitrile or methanol, or SPE (mixed-mode or reversed-phase) if cleaner extracts are required. Optimize recovery for M1 with post-extraction spiking experiments.
• Chromatography (typical):
  • Column: C18 or phenyl-hexyl, 1.7–3 µm, 2.1 mm ID.
  • Mobile phase A: water + 0.1% formic acid or 5–10 mM ammonium formate/acetate.
  • Mobile phase B: acetonitrile or methanol.
  • Gradient: 5–95% B over 3–6 min (UHPLC). Adjust for resolution of niraparib vs. M1.
• Mass spectrometry:
  • Ionization: ESI positive is common for basic drug-like metabolites; confirm for M1 experimentally.
  • Source settings: tune for maximal response with minimal in-source fragmentation; monitor multiple transitions if MRM is used. Exact m/z values are not provided here.
• Stability checks: Assess bench-top, autosampler (4–10°C), freeze–thaw (≥3 cycles), and long-term stability per internal validation guidance.

All parameters should be optimized and validated for the specific lot and matrix.

Safety and Handling

Safety data specific to this item are not provided in the Product Data. Handle as a research chemical of unknown hazard profile and consult the SDS for authoritative guidance.

• GHS Classification/Pictograms/Signal Word/H-Statements: Not specified for this item; refer to SDS.
• Primary risks (general for drug metabolites): Potential for biological activity and unknown toxicity. Avoid inhalation, ingestion, and skin contact. Use containment appropriate for potent small molecules (weighing in a fume hood or ventilated enclosure).
• PPE: Lab coat, safety glasses, and disposable nitrile gloves; upgrade to double-gloving and sleeve covers when handling milligram quantities or preparing aerosols/sonications.
• Handling: Minimize dust and aerosol formation. Prepare stock solutions in closed vials. Use amber vials if photosensitivity is suspected.
• Incompatibilities (general): Strong oxidizers/reducers and reactive acylating/alkylating agents until compatibility is known. Avoid moisture ingress if the compound is hygroscopic (verify on CoA).
• First aid (overview): If on skin, wash with soap/water; if in eyes, rinse with water for several minutes; if inhaled, move to fresh air; if ingested, rinse mouth. Seek medical attention; present SDS.
• Waste: Dispose according to local regulations for organic laboratory waste; segregate halogenated/non-halogenated solvents used in preparation.
• Always defer to the SDS and institutional SOPs.

Solvent Selection

Niraparib metabolite M1 is primarily used as an analytical reference in bioanalytical and metabolism studies. Solvent choice should prioritize solubility, stability, and LC–MS compatibility.

• Stock preparation (typical practice):
  • DMSO (anhydrous) for concentrated stocks (e.g., 10–20 mg/mL), then dilute into water:acetonitrile or water:methanol with 0.1% formic acid for LC–MS.
  • Acetonitrile or methanol can be used directly for lower-concentration stocks when DMSO carryover is undesirable.
• Miscibility/compatibility (general):
  • Water miscibility depends on ionization state; adding 0.1% formic acid (positive mode) or 2–10 mM ammonium acetate (negative/neutral) often improves peak shape.
  • Avoid high salt buffers in ESI to reduce ion suppression.
• Dielectric/polarity (general):
  • ACN (ε ~36) and MeOH (ε ~33, literature) are standard LC eluents; DMSO (ε ~47) for stocks only due to viscosity and ion suppression at high %.
• When to choose what:
  • Choose DMSO for maximum solubility and stability in frozen aliquots.
  • Prefer ACN for precipitation workflows (protein crash) and sharper LC peaks.
  • Use MeOH when improved solvation of polar metabolites is needed or to modify selectivity.
• Always verify solvent effects on recovery, adsorption, and MS response during method development.

Storage and Reconstitution

• Storage Conditions (item-specific): Store at -80°C. Keep container tightly closed under dry, inert conditions if possible. Minimize freeze–thaw by aliquoting upon first use.
• Shipping (item-specific): Shipped on dry ice packs + cold packs to maintain low temperature during transit.
• Stability guidance (general):
  • Long-term stability is maximized at -80°C protected from light and moisture. Verify retest/expiry on the CoA.
  • For working solutions, store at -20°C (short term) or 4–10°C in the autosampler as method permits; confirm stability experimentally.
• Reconstitution (general):
  • Allow vial to warm in a desiccator to room temperature before opening to prevent moisture condensation.
  • Dissolve in anhydrous DMSO to prepare a concentrated master stock. Alternative solvents (acetonitrile or methanol) may be used depending on required concentration and compatibility.
  • Filter (0.2 µm PTFE) if particulate is observed; avoid filters that adsorb analyte (test recovery if filtering).
• Aliquoting:
  • Prepare single-use aliquots to avoid repeat freeze–thaw. Label with concentration, solvent, preparation date, and purity correction.

Always consult the CoA and SDS for lot-specific stability and handling details.

Structure and Identity

Overview: Niraparib metabolite M1 is a defined biotransformation product of the PARP inhibitor niraparib, supplied for analytical and research use (not for clinical use).

• SKU: N655679
• Product Name: Niraparib metabolite M1
• CAS: 1476777-06-6
• PubChem CID: 118737587
• Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general, literature):

• Metabolites labeled “M1” for small-molecule drugs commonly represent the primary oxidative or dealkylated species identified in human or preclinical metabolism studies. For niraparib, reported pathways include oxidative transformations and conjugations (general literature). The exact structure of M1 for this product should be confirmed from the Certificate of Analysis (CoA) or Spectral Data provided with the lot.
• 2D structure description: Not specified for this item; refer to CoA/Spec Sheet.

Identity confirmation best practices:

• Verify by high-resolution MS (accurate mass and isotope pattern), 1H/13C NMR, and comparative LC retention vs. reference data where available.
• Use orthogonal purity/identity methods (HPLC/UPLC, LC–MS/MS) for method qualification in bioanalytical studies.

Synthetic Utility

As an isolated drug metabolite standard, Niraparib metabolite M1 is not typically employed as a general reagent or building block. However, context relevant to synthetic/analytical chemists includes:

• Benchmark for synthesis: Useful as an authentic target when developing or validating synthetic routes to niraparib metabolites (e.g., selective N-dealkylation, oxidation, or functional group interconversions). The exact structure of M1 should be verified from CoA/literature before route planning.
• Spectral reference: Serves as a comparator for NMR, MS, and chromatographic data when confirming structure and purity of in-house synthesized analogs or labeled standards.
• Derivatization (analytical): If sensitivity requires, metabolite standards may be derivatized (e.g., dansylation of amines or carbonyl derivatization) to enhance detection; assess compatibility with the M1 functional groups once confirmed.

Note: No claims are made regarding reactivity or compatibility in named reactions for this item without a disclosed structure. Any synthetic use should be guided by the verified functional groups of M1.

Target Specificity

Not applicable. This product is a small-molecule metabolite standard and not a biological macromolecule or affinity reagent. No antigen/epitope or species specificity data apply.

Frequently Asked Questions

How should this product be stored?

Store at ?80 °C. Ultra-low temperature storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships frozen with dry ice and cold packs. Unpack on arrival and transfer it to the storage condition stated above; handle dry ice with insulated gloves in a ventilated area.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 1476777-06-6, the molecular formula is C19H19N3O2, and the molecular weight is 321.37 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.